Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
← catalyst calendarNCT05753501 · readout ≤ 1,685 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
135actual
Sites
51
Countries
Canada, France, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-09 | actual | When the study began enrolling |
| Primary completion | Mar 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hematologic Cancer
Interventions
- Drug: ABBV-101
- Drug: Venetoclax
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AE)
measured Up to Approximately 100 Months
Change in Laboratory Parameters
measured Up to Approximately Two Years
Change in Vital Signs
measured Up to Approximately Two Years
Change in Electrocardiogram (ECG)
measured Up to Approximately Two Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed